Appropriate use of analgesics, sedatives, and neuromuscular blocking agents in the pediatric intensive care unit

1990 ◽  
Vol 2 (3) ◽  
pp. 538-542 ◽  
Author(s):  
William G. Keyes ◽  
Peter R. Holbrook
2010 ◽  
pp. 1155-1172
Author(s):  
Rodger E. Barnette ◽  
Ihab R. Kamel ◽  
Lilibeth Fermin ◽  
Gerard J. Criner

1993 ◽  
Vol 11 (2) ◽  
pp. 345-360 ◽  
Author(s):  
Sandor Agoston ◽  
Michaela Seyr ◽  
Karin S. Khuenl-Brady ◽  
Robert H. Henning

PEDIATRICS ◽  
1987 ◽  
Vol 79 (5) ◽  
pp. 841-842
Author(s):  
ANDRE L. VAN DER HAL ◽  
HUGH M. MACDONALD ◽  
LAURENCE SHAW ◽  
SUKSHMA SREEPATHI ◽  
SCOTT A. BEASLEY

To the Editor.— Recent letters to the Editors1,2 suggested discontinuation of clinical trials with doxapram for apnea of prematurity, because the preparation contains the preservative benzyl alcohol, implicated as the cause for the gasping syndrome at doses of 94 to 245 mg/kg/d.3 After we reexamined our standard arsenal of drugs used in the neonatal intensive care unit, we found an additional class of drugs containing benzyl alcohol: neuromuscular blocking agents. Pancuronium bromide (Pavulon, [Organon]) is prepared in 1-mg/mL vials containing 1% (10 mg/mL) benzyl alcohol.


Sign in / Sign up

Export Citation Format

Share Document